U of U Health

No Rating Available?

10 4.7 out of 5 Patient Rating

Languages Spoken: English

Dr. Siwen Hu-Lieskovan is an Assistant Professor of Medicine on Tenure Track, and Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute, University of Utah. She is a recent recruit from UCLA, where she received her Hematology/Oncology Fellowship training and held a faculty position under the mentorship of Dr. Antoni Ribas. She is a board-certified oncologist with clinical focus on melanoma and early phase testing of cancer immunotherapies in solid tumors. She is experienced with protocol development and conduct of immunotherapy-based clinical trials, and has been a principal investigator of industry-, investigator- and cooperative group-initiated clinical trials testing immune checkpoint inhibitors, oncolytic viruses, cancer vaccines and other immune-modulatory agents, as well as cell therapy with genetically modified T cells and hematopoietic stem cells. Dr. Hu-Lieskovan chairs the SWOG Immunotherapeutics Committee, and is a study chair and translational lead of several cross-NCTN protocols initiated by SWOG. She is also a consultant on oncology drug development strategies for the pharmaceutical and biotechnology industry.

Dr. Hu-Lieskovan is a physician scientist with research focus on characterization of tumor immune microenvironment, development of biomarkers to predict response to immunotherapies, and combination strategies to overcome the cancer immune resistance mechanisms, by studying patient-derived clinical samples and immune-competent (syngeneic) animal models. In the past, she and her research teams made contributions in understanding the role of driver mutations in oncogenesis and immune evasion, mechanisms of response and resistance to immune checkpoint inhibitors, and developing novel drug delivery systems. She led the first studies showing efficacy of nanoparticle delivered siRNA targeting oncogenes in treating metastatic cancers, and synergistic effect of combining BRAF and MEK inhibitors with immunotherapy in BRAF mutant melanoma. She has authored/co-authored research articles, reviews, editorials and book chapters in peer-reviewed journals including Nature, Science Translational Medicine, Cell, New England Journal of Medicine, etc. She is a recipient of the prestigious American Society of Clinical Oncologist (ASCO) Young Investigator Award (YIA) and Career Development Award, the Stand Up To Cancer (SU2C)/ American Association for Cancer Research (AACR) Sharp Award, the Hope Foundation Dr. Coltman Award, the Melanoma Research Alliance YIA and Team Science Award, the Tower Research Foundation Award, the UCLA KL2 Translational Award, the Daniel Von Hoff Innovative Protocol Award, as well as others. Siwen is a member of the SWOG melanoma committee working group, SITC Biomarker Taskforce, ASCO, and AACR. She was an associate director of the UCLA Parker Institute of Cancer Immunotherapy supervising biobanking and translational studies. She currently serves as a co-chair of the SITC Biomarker Taskforce Resources and Useful Tool Subcommittee.

Academic Departments	Internal Medicine - Assistant Professor
Academic Divisions	Oncology
Board Certification	American Board of Internal Medicine American Board of Internal Medicine (Sub: Medical Oncology)

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Learn About Our Survey

Likelihood of recommending care provider

4.7/ 5

Care provider's explanation of condition/problem

4.7/ 5

Care provider's effort to include me in decisions

4.7/ 5

Wait time at clinic

4.1/ 5

Care provider's concern for questions & worries

4.6/ 5

Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

UofU Patient June 27, 2020
HUNTSMAN CANCER CENTER

Dr. was very thorough and took her time to listen and answer all questions. You could tell she cares for the well being of her patients

UofU Patient May 30, 2020
HUNTSMAN CANCER CENTER

Dr. Hu thoroughly explained everything thoroughly - scan and lab results and my overall general health. She is very easy to talk to, listening and responding to all of my questions and concerns.

UofU Patient May 19, 2020
HUNTSMAN CANCER CENTER

Dr. Hu took the time needed to talk to me and answer my questions. She seemed relaxed and not rushed as she spoke with me, one-on-one. I really appreciated this personal care.

UofU Patient January 18, 2020
HUNTSMAN CANCER CENTER

The doctor encouraged me to not try to understand the biology. I know the biology of my tumor and my body is complicated, and that with my level of knowledge I was probably not making sense in some things I said when asking questions, but I would have appreciated a greater attempt to fill the gaps in my knowlege rather than the response I received. Maybe this is too much to ask for, particularly considering that the doctor's priorities that day were likely driven by patients with more urgent needs than mine, but attempting to inform and educate me as completely as possible is what I consider the ideal response from a doctor. Perhaps referring me to a medical textbook or some research papers that could help the problem of my lack of ability to understand the biology would have been a more appropriate response than for the doctor to tell me not to try to understand it.

UofU Patient January 04, 2020
HUNTSMAN CANCER CENTER

Hu was very thorough in my evaluation. She spent a good deal of time helping me to understand what I was up against and ideas for further treatment.

UofU Patient December 26, 2019
HUNTSMAN CANCER CENTER

Dr Hu was fantastic. She listens and cares for her patients.

UofU Patient September 23, 2019
HUNTSMAN CANCER CENTER

Referred me to oncological surgeon - scheduled for next Tuesday - Great!

UofU Patient September 22, 2019
HUNTSMAN CANCER CENTER

Dr, Hu was very helpful in answering our newest round of questions and spent a considerable amount of time talking to us, which was greatly appreciated. Dr. Wu is one of my favorites!

UofU Patient May 06, 2019
HUNTSMAN CANCER CENTER

provider well educated about my condition and was very compassionate in the delivery up information.

UofU Patient March 09, 2019
HUNTSMAN CANCER CENTER

it could not have been any better. thank you everyone.

Academic Locations

801-585-0308

Dr. Hu-Lieskovan’s laboratory uses cutting-edge technologies to investigate mechanisms of resistance to immunotherapy, develop novel combination strategies to overcome resistance, improve efficacy, as well as monitor and prevent immunotherapy-induced toxicities. Her team also conducts clinical trials to bring the discovery from her laboratory to the clinic, to improve the effectiveness and tolerability of immunotherapy, with the ultimate goal of bringing the survival benefit of immunotherapy to every patient.

Academic Departments	Internal Medicine - Assistant Professor
Academic Divisions	Oncology
Board Certification	American Board of Internal Medicine American Board of Internal Medicine (Sub: Medical Oncology)

Fellowship	David Geffen School of Medicine, University of California Los Angeles Hematology/Oncology Clinical Fellow
Internship/Residency	University of Southern California Internal Medicine Intern/Resident
Postdoctoral Fellowship	Children’s Hospital Los Angeles Pathology Postdoctoral Fellow
Doctoral Training	Keck School of Medicine, University of Southern California Pathobiology Ph.D.
Professional Medical	China Medical University Medicine M.D.

Journal Article

Torrejon DY, Abril-Rodriguez G, Champhekar AS, Tsoi J, Campbell KM, Kalbasi A, Parisi G, Zaretsky JM, Garcia-Diaz A, Puig-Saus C, Cheung-Lau G, Wohlwender T, Krystofinski P, Vega-Crespo A, Lee CM, Mascaro P, Grasso CS, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Ribas A (2020). Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade. Cancer Discov, 10(8), 1140-1157.
Grossman D, Okwundu N, Bartlett EK, Marchetti MA, Othus M, Coit DG, Hartman RI, Leachman SA, Berry EG, Korde L, Lee SJ, Bar-Eli M, Berwick M, Bowles T, Buchbinder EI, Burton EM, Chu EY, Curiel-Lewandrowski C, Curtis JA, Daud A, Deacon DC, Ferris LK, Gershenwald JE, Grossmann KF, Hu-Lieskovan S, Hyngstrom J, Jeter JM, Judson-Torres RL, Kendra KL, Kim CC, Kirkwood JM, Lawson DH, Leming PD, Long GV, Marghoob AA, Mehnert JM, Ming ME, Nelson KC, Polsky D, Scolyer RA, Smith EA, Sondak VK, Stark MS, Stein JA, Thompson JA, Thompson JF, Venna SS, Wei ML, Swetter SM (2020). Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol.
Parisi G, Saco J, Salazar F, Tsoi J, Krystofinski P, Puig Saus C, Zhang R, Zhou J, Cheung-Lau G, Garcia AJ, Grasso CS, Tavar R, Hu-Lieskovan S, Mackay S, Zalevsky J, Bernatchez C, Diab A, Wu A, Comin-Anduix B, Charych DH, Ribas A (Jan 2020). Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. Nat Commun, 11(1), 660.
Abril-Rodriguez G, Torrejon T, Zaretsky J, Nowicki T, Tsoi J, Baselga Carretero I, Medina E, Quist M, Senapedis W, Baloglu E, Cheung-Lau G, Puig-Saus C, Berent-Maoz B, Comin-Anduix B, Hu-Lieskovan S, Grasso C, Ribas A (Jan 2020). PAK4 inhibition reverses T cell exclusion in cancer and improves PD-1 blockade immunotherapy. Nature Cancer, 1, 46-58.
Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, Ying J, Hyngstrom JR (Nov 2019). Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med.
Zhu Y, Smith DJ, Zhou Y, Li YR, Yu J, Lee D, Wang YC, Di Biase S, Wang X, Hardoy C, Ku J, Tsao T, Lin LJ, Pham AT, Moon H, McLaughlin J, Cheng D, Hollis RP, Campo-Fernandez B, Urbinati F, Wei L, Pang L, Rezek V, Berent-Maoz B, Macabali MH, Gjertson D, Wang X, Galic Z, Kitchen SG, An DS, Hu-Lieskovan S, Kaplan-Lefko PJ, De Oliveira SN, Seet CS, Larson SM, Forman SJ, Heath JR, Zack JA, Crooks GM, Radu CG, Ribas A, Kohn DB, Witte ON, Yang L (Oct 2019). Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer. Cell Stem Cell, 25(4), 542-557.e9.
Johnson ML, Braiteh F, Grilley-Olson JE, Chou J, Davda J, Forgie A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S (May 2019). Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. JAMA Oncol.
Hu-Lieskovan S, Lisberg A, Zaretsky J, Wells D, Han M, Shintaku I, Wolf B, Abarca P, Slamon D, Goldman JW, Dubinett S, Ribas A, Garon EB (May 2019). Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer. Clin Cancer Res.
Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS (May 2019). Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis. Journal for Immunotherapy of Cancer, 7(1), 119.
Nowicki T, Berent-Maoz B, Cheung-Lau G, Huang RR, Wang X, Tsoi J, Kaplan-Lefko P, Cabrera P, Tran J, Pang J, Macabali M, Garcilazo IP, Carretero IB, Kalbasi A, Cochran A, Grasso C, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A (Apr 2019). A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination With or Without Ipilimumab. Clin Cancer Res, 25(7), 2096-2108.
Bethune MT, Li XH, Yu J, McLaughlin J, Cheng D, Mathis C, Moreno BH, Woods K, Knights AJ, Garcia-Diaz A, Wong S, Hu-Lieskovan S, Puig-Saus C, Cebon J, Ribas A, Yang L, Witte ON, Baltimore D (Oct 2018). Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. Proc Natl Acad Sci U S A.
Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT (Jun 2018). Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. . Clin Cancer Res.
Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski PE, Leiserson MD, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U (Mar 2018). Genetic mechanisms of immune evasion in colorectal cancer. Cancer Discov.
Eroglu Z Zaretsky J Hu-Lieskovan S Kim DW, Algazi A, Johnson D, Liniker E, Kong B, Munhoz R, Rapisuwon S, Chmielowski B, Homet Moreno B, Cherry G, Berent-Maoz B, Comin-Anduix B, Wang X, Tumeh PC, Shintaku IP, Hugo W, Lo RS, Sosman JA, Joseph R, Postow M, Hwu W-J, Messina J, Long G, Ribas A Equal contribution as first authors, Corresponding authors (Jan 2018). High response to PD-1 blockadein desmoplastic melanoma. Nature, 553(7688), 347-350.
Tolcher A, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, Di Gravio D, Huang B, Gambhire D, Chen Y, Thall AD, Pathan N, Schmidt EV, Chow LQ (Jun 2017). Phase Ib study of utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with pembrolizumab in patients with advanced solid tumors. Clin Cancer Res.
Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A (2017). Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Cell Rep, 19(6), 1189-1201.
Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, Palaskas N, Abril Rodriguez G, Parisi G, Azhdam A, Chmielowski B, Cherry G, Seja E, Berent-Maoz B, Shintaku IP, Le DT, Pardoll DM, Diaz LA, Tumeh PC, Graeber TG, Lo RS, Comin-Anduix B, Ribas A (Nov 2016). Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov.
Homet Moreno B, Zaretsky JM, Garcia-Diaz A, Tsoi J, Parisi G, Robert L, Meeth K, Ndoye A, Bosenberg M, Weeraratna AT, Graeber TG, Comin-Anduix B, Hu-Lieskovan S Ribas A Corresponding Authors (Oct 2016). Response to programmed cell death-1 blockade in a murine melanoma syngeneic model requires costimulation, CD4, and CD8 T cells. Cancer Immunol Res, 4(10), 845-857.
Zaretsky JM, Garcia Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Rodriguez GA, Sandoval S, Barthly L, Saco J, Homet Moreno B, Mezzadra R, Chmielowski B, Ruchalski K, Shintaku IP, Sanchez P, Puig-Saus C, Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B, Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher T, Lo RS, Ribas A (Sep 2016). Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. N Engl J Med, 375(9), 819-29.
Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS (Mar 2016). Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell, 165(1), 35-44.
Homet Moreno B, Mok S, Robert L, Comin-Anduix B, Hu-Lieskovan S, Ribas A (Aug 2015). Combined Treatment with Dabrafenib and Trametinib with Immune-stimulating Antibodies for BRAF Mutant Melanoma. Oncoimmunology, 5(7), e1052212.
Mok S, Tsoi J, Koya RC, Hu-Lieskovan S, West BL, Bollag G, Graeber TG, Ribas A (May 2015). Inhibition of CSF-1R Improves Antitumor Efficacy of BRAF Inhibition. BMC Cancer, 15(1), 356.
Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Koya KC, Graeber T, Comin-Anduix B, Ribas A (Mar 2015). Improved Antitumor Activity of Immunotherapy with BRAF and MEK inhibitors in BRAFV600E mutant melanoma. Sci Transl Med, 7(279), 279.
Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hlscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rdel C, Bracko M, Velenik V, Lenz HJ (Aug 2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. . Clin Cancer Res, 17(15), 5161-9.
Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ (Jan 2011). A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol, 22(1), 104-9.
Zwerner P, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May WA (May 2008). The EWS/FLI1 oncogenic transcription factor deregulates GLI1. Oncogene, 27(23), 3282-91.
Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ (Oct 2005). Sequence-specific knockdown of EWS-FLI1 by targeted, non-viral delivery of siRNA inhibits tumor growth in a murine model of metastatic Ewing’s sarcoma. Cancer Res, 65(19), 8984-8992.
Popielarski SR, Hu-Lieskovan S, French SW, Triche TJ, Davis ME (Aug 2005). A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 2. In vitro and in vivo uptake results. Bioconjug Chem, 16(5), 1071-80.
Hu-Lieskovan S, Zhang J, Schofield DE, Shimada H, Wu L, Triche TJ (Jun 2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing’s family of tumors. Cancer Res, 65(11), 4633-44.
Heidel JD, Hu S, Liu XF, Triche TJ, Davis ME (Dec 2004). Lack of interferon response in animals to naked siRNAs. Nat Biotechnol, 22(12), 1579-82.
Zhang J, Hu S, Schofield D, Sorensen P, Triche TJ (Sep 2004). Selective usage of D type cyclins by Ewing's tumors and rhabdomyosarcomas. Oncogene, 64(17), 6026-34.
Wang H, Hu S, Zhang J (Jul 2000). Expression of T cell receptor Va gene families in intrathyroidal T cells of Chinese patients with Graves’ disease (in English)Expression of T cell receptor Va gene families in intrathyroidal T cells of Chinese patients with Graves’ disease (in English). Chin Med Sci J, 15(3), 175-9.

Review

Moser J, Hu-Lieskovan S (Apr 2020). Mechanisms of Resistance to PD-1 Checkpoint Blockade. [Review]. Drugs, 80(5), 459-465.
Davda J, Declerck P, Hu-Lieskovan S, Hickling T, Jacobs I, Chou J, Salek-Ardakani S, Kraynov E (April 2019). Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. [Review]. J Immunother Cancer, 7, Article: 105.
Nowicki T, Hu-Lieskovan S, Ribas A (Jan/Feb 2018). Mechanisms of Resistance to PD-1 and PD-L1 blockade. [Review]. Cancer J, 24(1), 47-53.
Sharma P, Hu-Lieskovan S, Wargo J, Ribas A (February 2017). Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. [Review]. Cell, 168(4), 707-723.
Hu-Lieskovan S, Ribas R (Jan/Feb 2017). New combination strategies using PD-1/ L1 checkpoint inhibitors as a backbone. [Review]. Cancer J, 23(1), 10-22.
Ribas A, Hu-Lieskovan S (November 2016). What does PD-L1 positive or negative tumors mean? Perspective for Clinical Correlates of Immunotherapy. [Review]. J Exp Med, 213(13), 2835-2840.
Robert L, Ribas A, Hu-Lieskovan S (February 2016). Combining targeted therapy with immunotherapy. Can 1 + 1 equal more than 2? [Review]. Semin Immunol, 28(1), 73-80.
Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A (July 2014). Combining targeted therapy with immunotherapy in BRAF mutant melanoma: promise and challenges. [Review]. J Clin Oncol, 32(21), 2248-2254.
Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel J-C, Gupta S, Hanks B, Janetzki S, Kleen T, Koguchi Y, Lund A, Maccali C, Mahnke Y, Novosiadly R, Selvan S, Sims T, Zhao Y, Maecker H (Jan 2020: In Press). SITC Cancer Immunotherapy Resource Document - A Compass in the Land of Biomarker Discovery. [Review]. J Immunother Cancer.

Book Chapter

McKean W, Moser J, Rimm D, Hu-Lieskovan S (2020). Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. In ASCO Educational Book 40 (2020) (pp. e275-e291).
Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S (Jan 2019). Mechanisms of Resistance to Immune Checkpoint Blockade: Why Doesn't Checkpoint Inhibitor Immunotherapy Work for All Patients? In ASCO Educational Book 39 (2019) (pp. 147-164).
Hu-Lieskovan S, Chmielowski B, Ribas A (2017). Cancer Immunotherapy. In Chmielowski B, Territo MC (Eds.), Manual of Clinical Oncology (Eighth Edition). Lippincott Williams & Wilkins.
Sharma S, Hu-Lieskovan S, Dubinett SM, Moon Lee J (2015). Addressing inflammation with immunotherapy. In Dubinett S (Ed.), Inflammation and Lung Cancer (Second Edition). New York: Springer.

Editorial

Pal S, Hu-Lieskovan S, Agarwal N (Sep 2019). Can pegylated IL-10 add to a backbone of PD-1 inhibition for solid tumours? 20(11), 1473-1474.
Hu-Lieskovan S, Homet Moreno B, Ribas A (June 2018). Excluding T cells: Is β-catenin the full story? 27(6), 749-750.

Abstract

Hu-Lieskovan S, Braiteh F, Grilley-Olson J, Potluri S, Wang X, Forgie A, Bonato V, Chou J, Johnson M (July 2019). Predictive biomarkers and pharmacodynamic (PD) changes in tumor RNA expression in a phase I study of anti PD-1 monoclonal antibody (mAb) PF-06801591 [Abstract]. 79(13 Supplement), Abstract CT046.
Hu-Lieskovan S, Ott P, Naing A, Gates S, Kohler V, Curran R, Besada R, Bushway M, Scherer J, Balogh K, Scuito T, Ting Y, Rooney M, Harjanto D, Huang Z, Huang Y, Ware Y, Lamb A, Cleary L, Moles M, Gaynor R, Goldstein M, Brail L, Greshock J, Srinivasan L (July 2019). The personalized vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo immune responses in patients with advanced metastatic melanoma: correlations with clinical outcome [Abstract]. 79(13 Supplement), Abstract 942.
Torrejon D, Abril-Rodriguez G, Tsoi J, Champhekar A, Kalbasi A, Campbell K, Parisi G, Puig-Saus C, Cheung-Lau G, Wohlwender T, Berent-Maoz B, Grasso C, Comin-Anduix B, Hu-Lieskovan S, Ribas A (2019). Overcoming genetically based resistance mechanisms to PD-1 blockade [Abstract]. 37(15 Supplement), Abstract 2584.
Yap T, Papadopoulos K, LoRusso P, Wong D, Hu-Lieskovan S, Holz J-B (May 2019). A first-in-human phase I study of FS118, an anti-LAG-3/PD-L1 bispecific antibody in patients with solid tumors that have progressed on prior PD-1/PD-L1 therapy [Abstract]. 37(15 Supplement), TPS2652.
Evans E, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Howell A, Balch L, Leonard J, Fisher T, Allen C, Clavijo P, Lesinki G, Wu C, Hu-Lieskovan S, Ribas A, Greengard E, Smith E, Zauderer M (November 2018). Reprogramming suppressive myeloid cells in tumor microenvironment with pepinemab, first-in-class Semaphorin 4D Mab, enhances combination immunotherapy [Abstract]. O20.
Castro, D, Abril-Rodriguez G, Tsoi J, Champhekar A, Parisi G, Cheung-Lau G, Onyshchenko M, Berent-Maoz B, Grasso C, Comin-Anduix B, Hu-Lieskovan S, Ribas A (November 2018). Overcoming genetically-based PD-1 blockade resistance [Abstract]. Abstract P557.
Hu-Lieskovan S, Govindan R, Naing A, Griedlander T, Marolin K, Lin J, Bhardwaj N, Hellmann M, Srinivasan L, Greshcok J, Moles M, Gaynor R, Goldstein M, Ott P (November 2018). PAK4 inhibition reverses immune cell exclusion and overcomes resistance to checkpoint blockade therapy [Abstract]. Abstract O39.
Hu-Lieskovan S, Govindan R, Naing A, Friedlander T, Margolin K, Lin J, Bhardwaj N, Hellmann M, Srinivasan L, Greshcok J, Moles M, Gaynor R, Goldstein M, Ott P (November 2018). The personal vaccine, NEO-PV-01 with anti-PD1, induces neoantigen-specific de novo tumor-related immunity in patients with advanced cancer [Abstract]. Abstract O7.
Ott P, Govindan R, Niang A, Friedlander T, Margolin K, Lin J, Bhardwaj N, Hellmann M, Srinivasan L, Greshock J, Moles M, Gaynor R, Goldstein M, Hu-Lieskovan S (October 2018). A Personal Neoantigen Vaccine, NEO-PV-01, with anti-PD1 Induces Broad De Novo Anti-Tumor Immunity in Patients with Metastatic Melanoma, NSCLC, and Bladder Cancer [Abstract]. 29(Supplement 8), viii400-viii441.
Hamid O, Hu-Lieskovan S, Ros W, Diab A, El-Khoueiry A, Thompson J, Eskens F, X Doi T, Wasser J, Spano J, Angevin E, Rizvi N, Wasser J, Ott P, Chiappori A, Joh T, Krupka H, Potluri S, Wang X, Ganguly B, Chou J, Doi T (October 2018). Pharmacodynamic (PD) changes in tumors and peripheral blood T cell receptor (TCR) repertoire in a phase I study combining OX40 (PF-04518600) and 4-1BB (utomilumab) agonistic monoclonal antibodies (mAbs) [Abstract]. 29(Supplement 8), viii400-viii441.
Diab A, Hamid O, Thompson J, Schellens J, Eskens F, Doi T, Hu-Lieskovan S, Long H Joh T, Potluri S, Wang X, Fleener C, Taylor C, Ganguly B, Chou J, El-Khoueiry A (July 2018). Pharmacodynamic changes in tumor RNA expression and the peripheral blood T cell receptor (TCR) repertoire in a Phase I study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600 [Abstract]. 78(13 Supplement), Abstract CT010.
Ott P, Ramaswamy G, Naing A, Friedlander T, Margolin K, Lin J, Bhardwaj N, Hellmann M, Srinivasan L, Greshock J, Moles M, Gaynor R, Goldstein M, Hu-Lieskovan S (July 2018). A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer [Abstract]. 89(13 Supplement), Abstract CT125.
Evans E, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Howell A, Balch L, Leonard J, Fisher T, Allen C, Clavijo P, Lesinski G, Wu C, Hu-Lieskovan S, Ribas A, Greengard E, Smith E, Zauderer M (July 2018). Shifting the tumor microenvironment with first-in-class Semaphorin 4D mab for combination immunotherapy [Abstract]. 78(13 Supplement), Abstract 1762.
Parisi G, Saco J, Bergara F, Krstofinski P, Zhang R, Saus C, Hu-LIeskovan S, Comin-Anduix B, Wu A, Charych D, Ribas A (July 2018). Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214 [Abstract]. 78(13 Supplement), Abstract 3566.
Abril-Rodriguez G, Grasso C, Zaretsky J, Berent-Maoz B, Hu-Lieskovan S, Ribas A (July 2018). Role of PAK4 in cancer immune cell exclusion [Abstract]. 78(13 Supplement), Abstract 4755.
Nowicki T, Berent-Maoz B, Huang R, Wang X, Cheung-Lau G, Kaplan-Lefko P, Cabrera P, Tran J, Carretero I, Grasso C, Hu-Lieskovan S, Chmielowski B, Comin-Anduix B, Singh A, Ribas A (July 2018). A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab in patients with sarcoma and melanoma [Abstract]. 78(13 Supplement), CT008.
Lu H, Cummings A, Goldman J, Lisberg A, Hu-Lieskovan S, Grogan T, Gukasyan J, Madrigal J, Carroll J, Bornazyan K, Jones B, Noor Z, Zaretsky J, Elashoff D, Slamon D, Dubinett S, Garon E (June 2018). Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC) [Abstract]. 36(15 Supplement), Abstract 3025.
Kendra K, Moon J, Hu-Lieskovan S, Carson III W, Campos D, Cochran A, Wu M, Ribas A (June 2018). SWOG S1512: A phase II and pilot trial of Pembrolizumab in patients with resectable or unresectable desmoplastic melanoma (DM) [Abstract]. 36(15 Supplement), TPS9608.
Vandersalde A, Latkovic-Taber M, Hu-Lieskovan S, Grossmann K, Sosman J, Campos D, Wu M, Ribas A36 (June 2018). Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616) [Abstract]. 36(15 Supplement), TPS9597.
Hu-Lieskovan S, Torrejon D, Zaretsky J, Tsoi J, Cheung-Lau G, Vega-Crespo A, Meeth K, Prins R, Graeber T, Besenberg M, Grasso C, Comin-Anduix B, Rbias A (June 2018). Reversing resistance to PD-1 blockade by combination of talimogene laherparepvec (T-VEC) with pembrolizumab (pembro) in advanced melanoma patients following progression on a prior PD-1 inhibitor: SWOG S1607 (NCT#02965716) [Abstract]. 36(15 Supplement), TPS9603.
Hu-Lieskovan S, Torrejon D, Zaretsky J, Tsoi J, Cheung-Lau G, Vega-Crespo A, Meeth K, Prins R, Graeber T, Besenberg M, Grasso C, Comin-Anduix B, Rbias A (June 2018). CD4 cells are essential in the complete anti-tumor response to PD1 blockade in a syngeneic murine melanoma model with activated WNT signaling [Abstract]. 36(15 Supplement), 12013.
Evans E, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Balch L, Leonard J, Fisher T, Jenkins D, Allen C, Clavijo P, Hu-Lieskovan S, Ribas A, Smith E, Zauderer M (November 2017). Targeting the tumor microenvironment with first-in-class Semaphorin4D MAb for combination immunotherapy. [Abstract]. 5(87), Abstract P268.
Hamid O, Ros W, Thomson J, Hu-Lieskovan S, Eskens F, Diab A, Doi T, Wasser J, Spano J, Rizvi N, Angevin E, Chiappori A, Ott P, Ganguly B, Fleener C, Dell V, Liao K, Tenshang J, Chou J, El-Khoueiry A (September 2017). Safety, Pharmacokinetics and Pharmacodynamics Data from a Phase I Dose-Escalation Study of OX40 Agonistic Monoclonal Antibody (mAb) PF-04518600 in Combination with Utomilumab, A 4-1BB Agonistic mAb [Abstract]. 28(5 Supplement), v403-v427.
Hu-Lieskovan S, Braiteh F, Grilley-Olson J, Chou J, Davda J, Jin B, Forgie A, Rassam D, Youssef S, Johnson M (September 2017). Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF‑06801591, an anti-PD1 antibody administered intravenously (IV) or subcutaneously (SC) [Abstract]. 28(5 Supplement), v403-v427.
Ott P, Naing A, Ramaswamy G, Margolin K, Moles M, Gaynor R, Goldstein M, Hu-Lieskovan S (September 2017). An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder. [Abstract]. 28(5 Supplement), v403-v427.
Zaretsky J, Garcia-Diaz A, Shin D, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Eroglu Z, Torrejon D, Tumeh P, Lo R, Ribas A (July 2017). Mechanisms of resistance to anti-PD-1 immunotherapy through interferon pathway mutations [Abstract]. 77(13 Supplement), Abstract NG04.
Parisi G, Saco J, Hu-Lieskovan S, Zhang R, Krystofinski P, Puig Saus C, Charych D, Ribas A (July 2017). Antitumor activity of NKTR-214 in combination with pmel-1 ACT in an aggressive murine melanoma model [Abstract]. 77(13 Supplement), Abstract 2671.
Evans E, Bussler H, Mallow C, Reilly C, Torno S, Scrivens M, Foster C, Howell A, Comeau S, Balch L, Knapp A, Leonard J, Fisher T, Hu-Lieskovan S, Ribas A, Smith E, Zauderer M (July 2017). Breaking down the barrier restricting infiltration and differentiation of APC in the tumor microenvironment with a first-in-class antibody targeting Semaphorin4D, and rational combination therapies [Abstract]. 77(13 Supplement), Abstract 3661.
Hu-Lieskovan S, Eroglu Z, Zaretsky J, Kim D, Algazi A, Johnson D, Liniker E, Kong B, Munhoz R, Rapisuwon S, Chmielowski B, Sosman J, Scolyer R, Joseph R, Postow M, Carlina M, Hwu W-J, Long G, Ribas A (July 2017). Analysis of mutational burden and adaptive immune response in desmoplastic melanomas treated with PD-1/L1 inhibitors [Abstract]. 35(15 Supplement), Abstract 9558.
Naing A, HuLieskovan S, Govindan R, Margolin K, Moles M, Gaynor R, Goldstein M, Ott P (July 2017). An open‐label, Phase IB study of NEO‐PV‐01 + Adjuvant with Nivolumab in Patients with Melanoma, Non‐Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder [Abstract]. 35(15 Supplement), Abstract TPS3116.
Torrejon D, Zaretsky J, Shin D, Onyshchenko M, Abril-Rodriguez G, Vega-Crespo A, Puig-Saus C, Cheung-Lau G, Long C, Comin-Anduix B, Hu-Lieskovan S, Ribas A (July 2017). Interrogating resistance mechanisms to PD-1 blockade therapy with CRISPR [Abstract]. 35(15 Supplement), Abstract 3077.
El-Khoueiry A, Hamid O, Thompson JA, Ros W, Eskens FA, Doi T, Hu-Lieskovan S, Chou J, Liao K, Ganguly BJ, Fleener CA, Joh T, Diab A (2017). The Relationship of Pharmacodynamics (PD) and Pharmacokinetics (PK) to Clinical Outcomes in a Phase I Study of OX40 Agonistic Monoclonal Antibody (mAb) PF-04518600 (PF-8600) [Abstract]. 35(15 Supplement), Abstract 3027.
Tolcher A, Sznol M, Hu-Lieskovan S, Papadopoulos K, Patnaik A, Rasco D, DiGravio D, Huang8 B, Gambhire D, Chen Y, Pathan N, Wang K, Schmidt E, Chow L (June 2016). Phase 1b Study of Pf 05082566 in Combination With Pembrolizumab in Patients with Advanced Solid Tumors [Abstract]. 34(15 Supplement), Abstract 3002.
Evans E, Hu-Lieskovan S, Bussler H, Torno S, Mallow C, Reilly C, Scrivens M, Klimatcheva K, Winter LA, Kirk R, Howell A, Balch L, Veerarghavan J, Jonason Jr A, Leonard J, Paris M, Fisher T, Ribas T, Smith E, Zauderer M (December 2015). Antibody blockade of Semaphorin 4D Breaks Down Barriers To Enhance Tumoricidal Immune Infiltration And Supports Rational Immunotherapy Combinations [Abstract]. (4), Poster 1494.
Hu-Lieskovan S, Patnaik A, Eisenberg P, Sachdev J, Weise A, PLX and Merck, Ribas T (November 2015). Phase 1/2a Study of Double Immune Suppression Blockade by Combining a CSF1R Inhibitor (Pexidartinib/PLX3397) with an anti PD-1 Antibody (Pembrolizumab) to Treat Advanced Melanoma and Other Solid Tumors [Abstract]. 26(Supplement 8), vii5.
Hu-Lieskovan S, Mok S, Robert L, Goedert L, Comin-Anduix B, Koya RC, Ribas A (June 2014). Combinatorial effect of dabrafenib, trametinib, and adoptive cell transfer (ACT) in an immune-competent murine model of BRAFV600E mutant melanoma [Abstract]. 32(5 Supplement), Abstract 2512.
Winder T, Zhang W, Yang D, Ning Y, Bohanes PO, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EKLenz H (June 2010). Use of germ-line polymorphisms in genes involved in the IGF pathway to predict efficacy of cetuximab independent of K-ras in mCRC patients (IMCL-0144) [Abstract]. 28(15 Supplement), Abstract 3562.
Hu-LIeskovan S, Yang D, Grimminger PP, Arnold D, Dellas K, Machiels JH, Roedel C, Velenik V, Lenz H, Vallbohmer D (June 2010). Use of EGFa+61G and TS-5’UTR 2R/3R polymorphisms to predict complete pathologic response in locally advanced rectal cancer patients undergoing preoperative cetuximab-based chemoradiation followed by surgery [Abstract]. 28(15 Supplement), Abrtact 3641.
Zwerner J, Warner K, Christensen L, Hu-Lieskovan S, Triche T, May W (May 2008). The EWS/FLI1 oncogenic transcription factor deregulates GLI1 [Abstract]. 68(9), 865.
Hu S, Zhang J, Liu X-F, Schofield D, Triche T (June 2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed molecular phenotype of Ewing’s family of tumors [Abstract]. 65(9 Supplement), 4633-4644.
Schluep T, Jensen GS, Chen J, Heidel JD, Bartlett DW, Hu S, Triche TJ, Davis ME (June 2005). Camptothecin-polymer conjugate shows improved biodistribution and preclinical efficacy in vivo [Abstract]. 46(9 Supplement), 328.
Hu S, H JD, B DW, K DB, D ME, T TJ (May 2005). Systemic targeted EWS-FLI1 siRNA abrogates growth of metastases in a murine Ewing’s tumor model [Abstract]. 65(9 Supplement), 1435-1436.
Heidel JD, Hu-Lieskvoan S, Bartlett DW, Triche TJ, Davis ME (May 2005). Systemic Administration of siRNA Against EWS-FLI1 Using a Targeted, Non-Viral Formulation Inhibits Growth in a Disseminated Murine Model of Ewing's Sarcoma [Abstract]. 11(Supplement 1), S28-S29.

Video/Film/CD/Web/Podcast

Hu-Lieskovan S, Ribas A (2013). ASCO 2013 Highlights: Melanoma (review) [Web]. Available: Oncofacts.com.

Education History

Professional Medical

China Medical University
Medicine
M.D.

Siwen Hu-Lieskovan, PhD, MD

Specialties

Board Certification and Academic Information

Patient Rating

Patient Comments

Academic Locations

Huntsman Cancer Institute

Research Statement

Board Certification and Academic Information

Education History

Selected Publications - Journal Articles

Journal Article

Review

Book Chapter

Editorial

Abstract

Video/Film/CD/Web/Podcast

Global Impact

Education History

Huntsman Cancer Institute News

Melanoma Research Innovations

Immunotherapy Leads the Way for Melanoma Treatment